Such targeted mutagenesis allows to uncouple the pleiotropic effects of IL-2 on different immune cells and to target IL-2 activity toward specific cell populations that express either the dimeric IL-2R to boost tumour immunity or the trimeric IL-2R expressed by Treg to increase tolerance in autoimmunity and to transplanted grafts. The gene discussed is IL2RA; the disease is neoplasm.